Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
In a nationally representative US sample (NSDUH 2015–2019), lifetime peyote use was associated with a greater than 50% reduction in the odds of cocaine use disorder (adjusted OR 0.47) and lowered odds on seven of 11 CUD criteria, whereas psilocybin, LSD and mescaline showed no protective association or were linked to increased odds. The authors recommend studies to examine demographic, personality and contextual confounds and longitudinal research to determine causality and therapeutic potential.
Authors
- George Jones
- Matthew Nock
Published
Abstract
Cocaine Use Disorder (CUD) is a significant public health problem associated with elevated morbidity and mortality within the United States. Current behavioral treatments have limited efficacy and there are currently no FDA approved pharmacological treatments for CUD. Classic psychedelics might be associated with lowered odds of substance misuse and may effectively treat various forms of addiction. Thus, the goal of this study is to assess protective associations that lifetime use of classic psychedelics may share with CUD within a nationally representative sample of the U.S. We used data from The National Survey on Drug Use and Health (NSDUH) (2015–2019) and conducted survey-weighted multivariable logistic regression to test whether each of four classic psychedelics (peyote, mescaline, psilocybin, LSD) conferred lowered odds of CUD and its related 11 sub-criteria. Participants were 214,505 adults in the NSDUH (2015–2019) aged 18 and older. Peyote conferred lowered odds of CUD, reducing the odds of CUD by over 50% (aOR: 0.47). All other substances (including other classic psychedelics) either shared no association to CUD or conferred increased odds of CUD. Furthermore, sensitivity analyses revealed peyote to confer sharply lowered odds of the majority (seven of 11) of CUD criteria as well (aOR range: 0.26–0.47). Peyote use is associated with lowered odds of CUD. Future inquiries into third variable factors (i.e., demographic/personality profiles of individuals who use peyote, motivational/contextual factors surrounding peyote use) that may underlie our observed associations may reveal protective factors that can inform treatment development for CUD. Additionally, future longitudinal studies can shed further light on whether there is a temporal link between peyote use and lowered odds of CUD.
Research Summary of 'Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study'
Introduction
Cocaine use disorder (CUD) is described as a substantial public‑health problem in the United States, associated with elevated morbidity and mortality and with limited effective pharmacological treatments. Earlier research has suggested that naturalistic use of classic psychedelics is associated with lower odds of some deleterious outcomes and that psychedelics may have promise in treating addictive disorders, but population‑level evidence specifically linking individual classic psychedelics to CUD has been limited and inconsistent. Jones and colleagues set out to test whether lifetime use of four commonly reported classic psychedelics — peyote, mescaline, psilocybin and LSD — is associated with reduced odds of past‑year CUD. Using a large, nationally representative survey dataset, the investigators aimed both to examine associations with overall past‑year CUD and to probe which of the 11 DSM‑IV criteria for CUD might show protective associations, should any substance emerge as significant in the main analysis.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Jones, G. M., & Nock, M. K. (2022). Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-06580-2
References (30)
Papers cited by this study that are also in Blossom
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)
Barbosa, P., Tófoli, L.F., Bogenschutz, M. P. et al. · Frontiers in Psychiatry (2018)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Dakwar, E., Hart, C. L., Levin, F. R. et al. · Molecular Psychiatry (2016)
Dakwar, E., Nunes, E. V., Hart, C. L. et al. · American Journal of Psychiatry (2019)
Show all 30 referencesShow fewer
Dakwar, E., Nunes, E. V., Hart, C. L. et al. · Neuropharmacology (2018)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)
Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)
Agin-Liebes, G. I., Malone, T., Yalch, M. M. et al. · Journal of Psychopharmacology (2020)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Cohen, S. · Journal of Nervous and Mental Disease (1980)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)
Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)
Uthaug, M. V., Davis, A. K., Davis, D. et al. · Journal of Psychopharmacology (2021)
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)
Simonsson, O., Osika, W., Carhart-Harris, R. L. et al. · Scientific Reports (2021)
Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)
Erritzoe, D., Smith, J. M., Fisher, P. M. et al. · Journal of Psychopharmacology (2019)
Johnstad, P. G. · Journal of Psychoactive Drugs (2020)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Cited By (7)
Papers in Blossom that reference this study
Teixeira, P. J., Jain, R., Penn, A. D. et al. · Preventative Medicine Reports (2025)
Jones, G. M., Nock, M. K. · Frontiers in Psychiatry (2023)
Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
Hendricks, P. S., Simonsson, O. · Journal of Psychopharmacology (2022)
Jones, G. M., Lipson, J., Nock, M. K. · Scientific Reports (2022)
Jones, G. M., Ricard, J. A., Lipson, J. et al. · Scientific Reports (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.